Vantari Genetics, Irvine, Calif, and Translational Software Inc (TSI), Bellevue, Wash, have partnered to provide genotype testing, actionable genomic information, and custom reporting in support of the GeneMatch registry at Banner Alzheimer’s Institute (BAI). The GeneMatch registry is a national program that leverages genetic testing information to recruit participants for Alzheimer’s prevention studies.
Researchers have identified a number of genes associated with Alzheimer’s disease. The most common form of the disease is called late-onset Alzheimer’s, which usually begins after age 65 and is associated with a gene called apolipoprotein E (APOE).
Vantari Genetics and TSI are collaborating to support the GeneMatch program through APOE testing and interpreting the cheek swabs of volunteers interested in participating in community-based Alzheimer’s research opportunities. The raw genomic and molecular data from the tests are analyzed to provide scientific intelligence about the genetic variants of volunteers, which is used to identify study participants at varying degrees of genetic risk for developing Alzheimer’s disease, and to match them to available research studies.
Shaun Opie, PhD, Vantari Genetics.
“We are grateful to be part of a talented, multidisciplinary team supporting a clinical study infrastructure to help the Banner Azheimer’s Institute enroll and genotype volunteers to advance Alzheimer’s research,” says Shaun Opie, PhD, chief scientific officer at Vantari Genetics.
The companies will work together to provide BAI with in-depth analysis of the APOE data in multiple, customized formats that will be used to help scientists identify early brain changes in participants, and compare the effectiveness of treatments for people with different APOE profiles.
Don Rule, Translational Software.
“Our genomic platform is very flexible, which allows us to offer unique genomic testing solutions and data reporting capabilities that can be customized to support single-gene testing, in-depth interpretation and analysis, and the integration of independent clinical research,” says Don Rule, CEO of TSI. “We are pleased to be working with Vantari Genetics to support the important work that BAI is doing to help advance the study of genetic risk for Alzheimer’s.”
For more information, visit Translational Software and Vantari Genetics.
